Sherif El Harazi
Ophthalmology · Glendale, CANPI 1982714887
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Dompe US, Inc. accounts for 60.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $3,327 and has fallen 98.9% since, to $37 in 2025.
Across 105 payments — averaging $69.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$4K
- Aerie Pharmaceuticals, Inc.$930
- Novartis$590
- Bioverativ Therapeutics Inc.$500
- Glaukos Corporation$363
- Shire North American Group Inc$155
- plus $351 from 4 others
Across 576 payments — averaging $16,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.1M
- Oyster Point Pharma, Inc.$1.2M
- Glaukos Corporation$1M
- Bausch & Lomb Americas Inc.$755K
- Alcon Research LLC$671K
- Novartis$631K
- plus $1.9M from 15 others
What the payments were for
- Consulting fees$5007%
- Speaking & faculty fees$4,30059%
- Travel & lodging$591%
- Food & beverage$2,43033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 4 | $4,400 |
| Aerie Pharmaceuticals, Inc. | 49 | $930 |
| Novartis | 23 | $590 |
| Bioverativ Therapeutics Inc. | 1 | $500 |
| Glaukos Corporation | 9 | $363 |
| Shire North American Group Inc | 7 | $155 |
| Sun Pharmaceutical Industries Inc. | 6 | $135 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $98 |
| AbbVie | 4 | $96 |
| Akorn, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$1,500
How this compares
$7,288 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 58 | $521 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Glendale
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.